Mode
Text Size
Log in / Sign up
Phase 4 N=11 Randomized Double-blind Treatment

Is Treatment of Vitamin D Deficiency Associated With Resolution of Statin-Induced Muscular Symptoms

Myopathic Symptoms

Enrolled (actual)
11
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcome: Primary: Number of Participants With Reduction in Myopathic Pain — 4; 4 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Ergocalciferol (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Cedars-Sinai Medical Center
Primary completion
Jun 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Reduction in Myopathic Pain
4; 4
PRIMARY
Brief Pain Inventory (BPI) Severity at Exit
4.5625; 3.8125
PRIMARY
Vitamin 25 OH D Levels
18.075; 18.05
PRIMARY
Brief Pain Inventory (BPI) Interference at Exit
3.85714285725; 0.80952380967
SECONDARY
Lipid Profile - Total Cholesterol Levels
165.8; 197.67
SECONDARY
Lipid Profile - LDL Cholesterol Levels
88.4; 106.83
SECONDARY
Lipid Profile - HDL Cholesterol Levels
51.8; 63.5
SECONDARY
Lipid Profile - Triglycerides Levels
107.54; 86.92

Summary

Statins are a class of drugs that are highly effective at lowering cholesterol levels. However, compliance is often limited by symptoms of muscle pain. The investigators would like to study Vitamin-D deficient individuals who also have muscle pain due to statin use. About 1 billion people are estimated to have low or insufficient levels of vitamin D worldwide. Patients with low or insufficient levels of vitamin D may develop muscle disease. The purpose of this study is to identify if these symptoms are associated with vitamin D deficiency, and most importantly, if treatment of vitamin D deficiency can reduce muscle pain that is caused by statin treatment.

Eligibility Criteria

Inclusion Criteria

  • Female gender (refer to section 4)
  • Age > 18, using an effective form of contraception (refer to section 4)
  • An indication to be on statin therapy
  • Moderate to severe myopathic pain while on Simvastatin
  • Serum CK level 1000 IU/day
  • Serum creatinine > 2.2 mg/dL within last 6 months
  • AST/ALT > 3 x ULN of the local reference range
  • Serum CK level > 10 x ULN
  • Systolic blood pressure 2.55 mmol/L or < 2.20 mmol/L
  • Renal osteodystrophy
  • Malabsorption syndrome
  • Metastatic malignancy
  • Transplant recipients
  • A co-existent diagnosis of renal calculi within the previous 6 months
  • A co-existent diagnosis of primary hyperparathyroidism within the previous 6 months
  • Recent therapy with corticosteroids within the previous 6 months
  • Currently consuming Digoxin, as usage increases risk of hypercalcemia
  • Lactating women
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01568255). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search